BGLC
BioNexus Gene Lab Corp Common stock
NASDAQ: BGLC · BASIC MATERIALS · SPECIALTY CHEMICALS
$2.09
+1.46% today
Updated 2026-04-30
Market cap
$5.37M
P/E ratio
—
P/S ratio
0.72x
EPS (TTM)
$-1.61
Dividend yield
—
52W range
$2 – $16
Volume
0.0M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
2.0
Growth
F8.0
Quality
A2.0
Profitability
F6.7
Valuation
B2/9
Piotroski F-Score
Weak
2.3
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$—
—
12-Month target
—
—
Intrinsic (DCF)
$7.92
Margin of safety
+75.38%
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $930551.00 — positive
+ 75.38% below intrinsic value
+ Debt/equity 0.03x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at -40.20%
- Revenue declining -80.80% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $10.93M | $9.77M | $9.51M | $7.42M | $7.42M |
| Net income | $-355966.00 | $-2.63M | $-1.60M | $-2.98M | $-1.04M |
| EPS | — | — | — | — | $-1.61 |
| Free cash flow | $489857.00 | $-1.91M | $-2.46M | $-1.88M | $930551.00 |
| Profit margin | -3.26% | -26.91% | -16.81% | -40.20% | -40.20% |
Peer comparison
Smart narrative
BioNexus Gene Lab Corp Common stock trades at $2.09. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.31, it sits in the grey zone. TTM revenue stands at $7.42M. with profit margins at -40.20%. Our DCF model estimates intrinsic value at $7.92.
Frequently asked questions
What is BioNexus Gene Lab Corp Common stock's stock price?
BioNexus Gene Lab Corp Common stock (BGLC) trades at $2.09.
Is BioNexus Gene Lab Corp Common stock overvalued?
Smart Value Score 29/100 (Grade F, Strong Sell). DCF value $7.92.
What is the price target of BioNexus Gene Lab Corp Common stock (BGLC)?
The analyst target price is $—, representing NaN% downside from the current price of $2.09.
What is the intrinsic value of BioNexus Gene Lab Corp Common stock (BGLC)?
Based on our DCF model, intrinsic value is $7.92, a +75.4% margin of safety versus $2.09.
What is BioNexus Gene Lab Corp Common stock's revenue?
TTM revenue is $7.42M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
2.31 — grey zone.
Company info
SectorBASIC MATERIALS
IndustrySPECIALTY CHEMICALS
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.72x
ROE-35.20%
Beta2.31
50D MA$2.35
200D MA$4.11
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—